Machine learnINg for the rElapse Risk eValuation in Acute Biliary Pancreatitis.
NCT ID: NCT06124989
Last Updated: 2023-11-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Total Enrollment
430 participants
Study Classification
OBSERVATIONAL
Study Start Date
2024-01-01
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The MINERVA (Machine learnINg for the rElapse Risk eValuation in Acute biliary pancreatitis) project stems from the need in the clinical practice of taking an operational decision in patients that are admitted to the hospital with a diagnosis of acute biliary pancreatitis. In particular, the MINERVA prospective cohort study aims to develop a predictive score that allows to assess the risk of hospital readmission for patients diagnosed with mild biliary acute pancreatitis using Machine Learning and artificial intelligence.
The objectives of the MINERVA study are to:
1. Propose a novel methodology for the assessment of the risk of relapse in patients with mild biliary acute pancreatitis who did not undergo early cholecystectomy (within 3 to 7 days from hospital admission);
2. Propose a Machine Learning predictive model using a Deep Learning architecture applied to easily collectable data;
3. Validate the MINERVA score on an extensive, multicentric, prospective cohort;
4. Allow national and international clinicians, medical staff, researchers and the general audience to freely and easily access the MINERVA score computation and use it in their daily clinical practice.
The MINERVA score model will be developed on a retrospective cohort of patients (MANCTRA-1, already registered in ClinicalTrials.gov) and will be validated on a novel prospective multicentric cohort. After validation, the MINERVA score will be free and easy to compute instantly for all medical staff; it will be accessible at any time on the MINERVA website and web app, and will provide an immediate and reliable result that can be a clear indication for the best treatment pathway for the clinician and for the patient.
The objectives of the MINERVA study are to:
1. Propose a novel methodology for the assessment of the risk of relapse in patients with mild biliary acute pancreatitis who did not undergo early cholecystectomy (within 3 to 7 days from hospital admission);
2. Propose a Machine Learning predictive model using a Deep Learning architecture applied to easily collectable data;
3. Validate the MINERVA score on an extensive, multicentric, prospective cohort;
4. Allow national and international clinicians, medical staff, researchers and the general audience to freely and easily access the MINERVA score computation and use it in their daily clinical practice.
The MINERVA score model will be developed on a retrospective cohort of patients (MANCTRA-1, already registered in ClinicalTrials.gov) and will be validated on a novel prospective multicentric cohort. After validation, the MINERVA score will be free and easy to compute instantly for all medical staff; it will be accessible at any time on the MINERVA website and web app, and will provide an immediate and reliable result that can be a clear indication for the best treatment pathway for the clinician and for the patient.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PrEveNtion of Biliary Events After Acute Pancreatitis in NonSUrgicaL PAtients: PENINSULA Trial
NCT06409741
Acute Pancreatitis Due to Gallstones
Acute Pancreatitis
ENROLLING_BY_INVITATION
NA
coMpliAnce With evideNce-based cliniCal Guidelines in the managemenT of Acute biliaRy pancreAtitis
NCT04747990
Acute Pancreatitis
Acute Pancreatic Necrosis
Acute Pancreatitis Due to Gallstones
+7 more
COMPLETED
ANGH Prospective Cohort of Mild and Severe Acute Biliary Pancreatitis
NCT05549349
Acute Biliary Pancreatitis
TERMINATED
Observational Study to Develop a Predictive Score for Adverse Events Post ERCP
NCT06776874
Endoscopic Retrograde Cholangiopancreatography
RECRUITING
a Prediction of Post-Endoscopic Retrograde Cholangiopancreatography Complication
NCT06277414
Endoscopic Retrograde Cholangiopancreatography
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Acute pancreatitis is the most common pancreatic disease, with a global incidence of 34 cases per 100,000 individuals. This disease counts more than 1.5 million new patients per year worldwide, with a mortality that approaches 1%. Mild biliary acute pancreatitis patients, when admitted to the hospital, can be treated with index, early cholecystectomy (within 3 to 7 days from the acute episode) or conservatively. While conservative treatment can be resolutive, up to 35% of these patients have a relapse within 30 days, and require emergency surgery in a significantly worse overall patient condition, reducing the chances of success. Other than that, relapse dramatically increases the chances of chronic pancreatitis, pancreatic cancer, postoperative complications and overall mortality. Relapse episodes have also an economic impact on healthcare facilities, as a second and longer hospital admission per patient increases the overall medical cost per patient by at least 100%. So far, however, there are no standardised methods to predict relapse of biliary acute pancreatitis in patients who did not undergo early cholecystectomy after the first episode of mild biliary acute pancreatitis.
The MINERVA (Machine learnINg for the rElapse Risk eValuation in Acute biliary pancreatitis) project stems from the need in the clinical practice of taking an operational decision in patients that are admitted to the hospital with a diagnosis of mild acute biliary pancreatitis.
The MINERVA project aims to reach the following objectives and results:
1. Propose a novel methodology for the assessment of the risk of relapse in patients with mild biliary acute pancreatitis who did not undergo early cholecystectomy after the first episode of mild biliary acute pancreatitis;
2. Propose a Machine Learning predictive model using a Deep Learning architecture applied to data easy to collect from patients;
3. Validate the MINERVA score on an extensive, multicentric, prospective cohort;
4. Allow national and international clinicians, medical staff, researchers and the general audience to freely and easily access the MINERVA score computation and use it in their daily clinical practice.
The MINERVA score will provide the clinicians with a validated and standardized assessment of relapse risk that takes into account the personal history, demographic data and laboratory characteristics of each patient. The MINERVA score will be free and easy to compute instantly for all medical staff; it will be accessible at any time on the MINERVA website and web app, and will provide an immediate and reliable result that can be a clear indication for the best treatment pathway for the clinician and for the patient.
The MINERVA score model will be developed on a retrospective cohort of patients (MANCTRA-1, already registered in ClinicalTrials.gov) and will be validated on a novel prospective multicentric cohort.
Retrospective cohort The model development and initial training will be performed on a retrospective cohort of patients (n=692) collected during a preliminary multicentric study, the MANCTRA-1 study (approved by the Ethics Committee of the University of Cagliari Hospital, MANCTRA-1 - NCT04747990, Prot. PG/2021/7108) conducted by the PI (Dr. Mauro Podda) and the University of Cagliari local responsible of the MINERVA project.
Prospective cohort A total of 430 patients will be recruited in the prospective cohort of the MINERVA study.
Methods The MINERVA score will be grounded on a Machine Learning model that will be developed and trained on a retrospective cohort and validated on a prospective cohort of patients.
All model variables will be processed with kernel Principal Component Analysis (kPCA).
The Convex Hull of the scatterplot of the main components will be computed and the smallest rectangle will be extracted. The rectangle will be transformed into a 2d image with a fixed resolution using feature averaging and normalization.
The model will be developed at the University of Naples Federico II by Dr. Daniela Pacella with the Machine Learning expertise and supervision.
To prevent overfitting, the dataset will be split into training set, test set and validation set. Additionally, k-fold cross-validation will be used. The performance of the MINERVA model will be evaluated using the most adopted measures of accuracy, such as precision, recall and AUC (Area Under the ROC Curve). Additionally, its performance will be compared with that achieved using traditional machine learning methods (SVM, ANN). Missing data will be handled with imputation methods.
Variables Age (Years) Sex (Male:Female) Previous episodes of biliary pancreatitis (Yes; No) Admitting speciality (HepatoPancreatoBiliary surgery, General surgery, Internal medicine, Gastroenterology) Body mass index -BMI- (Kg/m2) Clinical history of diabetes (No diabetes; Yes with organ dysfunction; Yes without organ dysfunction) Clinical history of chronic pulmonary disease (Yes; No) Clinical history of hypertension (Yes; No) Clinical history of atrial fibrillation (Yes; No) Clinical history of ischemic heart disease (Yes; No) Clinical history of chronic kidney disease (No; Yes under medications; Yes in permanent renal replacement therapy or in preparation for it) Clinical history of of diseases of the hematopoietic system (Yes; No) Patient on immunosuppressive medications on hospital admission (Yes; No) White Blood Cells -WBC- (cells/mm3) Neutrophils (cells/mm3) Platelets (Plt/mm3) INR (International Normalized Ratio) C-reactive protein -CRP- (mg/L) Aspartate aminotransferase -AST- (U/L) Alanine aminotransferase -ALT- (U/L) Total bilirubin (mg/dL) Conjugated bilirubin (mg/dL) Gamma-glutamil-transpeptidase -GGT- (U/L) Serum amylase (U/L) Serum lipase (U/L) Lactate DeHydrogenase -LDH- (U/L) Choledocholithiasis (Yes; Yes with common bile duct obstruction; No) Cholangitis (Yes; No) ERCP with sphincterotomy (Yes within 24h from hospital admission; Yes within 24-48h from hospital admission; Yes within 48-72h from hospital admission; No) Acute biliary pancreatitis relapse at 30-day, 60-day, 90-day, 1 year.
The MINERVA (Machine learnINg for the rElapse Risk eValuation in Acute biliary pancreatitis) project stems from the need in the clinical practice of taking an operational decision in patients that are admitted to the hospital with a diagnosis of mild acute biliary pancreatitis.
The MINERVA project aims to reach the following objectives and results:
1. Propose a novel methodology for the assessment of the risk of relapse in patients with mild biliary acute pancreatitis who did not undergo early cholecystectomy after the first episode of mild biliary acute pancreatitis;
2. Propose a Machine Learning predictive model using a Deep Learning architecture applied to data easy to collect from patients;
3. Validate the MINERVA score on an extensive, multicentric, prospective cohort;
4. Allow national and international clinicians, medical staff, researchers and the general audience to freely and easily access the MINERVA score computation and use it in their daily clinical practice.
The MINERVA score will provide the clinicians with a validated and standardized assessment of relapse risk that takes into account the personal history, demographic data and laboratory characteristics of each patient. The MINERVA score will be free and easy to compute instantly for all medical staff; it will be accessible at any time on the MINERVA website and web app, and will provide an immediate and reliable result that can be a clear indication for the best treatment pathway for the clinician and for the patient.
The MINERVA score model will be developed on a retrospective cohort of patients (MANCTRA-1, already registered in ClinicalTrials.gov) and will be validated on a novel prospective multicentric cohort.
Retrospective cohort The model development and initial training will be performed on a retrospective cohort of patients (n=692) collected during a preliminary multicentric study, the MANCTRA-1 study (approved by the Ethics Committee of the University of Cagliari Hospital, MANCTRA-1 - NCT04747990, Prot. PG/2021/7108) conducted by the PI (Dr. Mauro Podda) and the University of Cagliari local responsible of the MINERVA project.
Prospective cohort A total of 430 patients will be recruited in the prospective cohort of the MINERVA study.
Methods The MINERVA score will be grounded on a Machine Learning model that will be developed and trained on a retrospective cohort and validated on a prospective cohort of patients.
All model variables will be processed with kernel Principal Component Analysis (kPCA).
The Convex Hull of the scatterplot of the main components will be computed and the smallest rectangle will be extracted. The rectangle will be transformed into a 2d image with a fixed resolution using feature averaging and normalization.
The model will be developed at the University of Naples Federico II by Dr. Daniela Pacella with the Machine Learning expertise and supervision.
To prevent overfitting, the dataset will be split into training set, test set and validation set. Additionally, k-fold cross-validation will be used. The performance of the MINERVA model will be evaluated using the most adopted measures of accuracy, such as precision, recall and AUC (Area Under the ROC Curve). Additionally, its performance will be compared with that achieved using traditional machine learning methods (SVM, ANN). Missing data will be handled with imputation methods.
Variables Age (Years) Sex (Male:Female) Previous episodes of biliary pancreatitis (Yes; No) Admitting speciality (HepatoPancreatoBiliary surgery, General surgery, Internal medicine, Gastroenterology) Body mass index -BMI- (Kg/m2) Clinical history of diabetes (No diabetes; Yes with organ dysfunction; Yes without organ dysfunction) Clinical history of chronic pulmonary disease (Yes; No) Clinical history of hypertension (Yes; No) Clinical history of atrial fibrillation (Yes; No) Clinical history of ischemic heart disease (Yes; No) Clinical history of chronic kidney disease (No; Yes under medications; Yes in permanent renal replacement therapy or in preparation for it) Clinical history of of diseases of the hematopoietic system (Yes; No) Patient on immunosuppressive medications on hospital admission (Yes; No) White Blood Cells -WBC- (cells/mm3) Neutrophils (cells/mm3) Platelets (Plt/mm3) INR (International Normalized Ratio) C-reactive protein -CRP- (mg/L) Aspartate aminotransferase -AST- (U/L) Alanine aminotransferase -ALT- (U/L) Total bilirubin (mg/dL) Conjugated bilirubin (mg/dL) Gamma-glutamil-transpeptidase -GGT- (U/L) Serum amylase (U/L) Serum lipase (U/L) Lactate DeHydrogenase -LDH- (U/L) Choledocholithiasis (Yes; Yes with common bile duct obstruction; No) Cholangitis (Yes; No) ERCP with sphincterotomy (Yes within 24h from hospital admission; Yes within 24-48h from hospital admission; Yes within 48-72h from hospital admission; No) Acute biliary pancreatitis relapse at 30-day, 60-day, 90-day, 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Acute Pancreatitis
Pancreatitis Due to Gallstones
Pancreatitis Biliary
Pancreatitis Relapsing
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MINERVA Machine Learning model
The MINERVA score for the prediction of the risk of relapse of acute pancreatitis in patients who did not undergo early cholecystectomy after the first episode of acute biliary pancreatitis will be grounded upon a Machine Learning model that takes into account patients' demographic, clinical, and laboratory variables that can be easily collected and recorded at index patient admission.
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patients (≥ 18 years old)
* Clinical diagnosis of mild biliary acute pancreatitis (according to the Revised Atlanta Classification)
* Not submitted to cholecystectomy or ERCP/ES (Endoscopic Retrograde CholangioPancreatography/Endoscopic Sphyncterotomy) during the same hospital admission
* Clinical diagnosis of mild biliary acute pancreatitis (according to the Revised Atlanta Classification)
* Not submitted to cholecystectomy or ERCP/ES (Endoscopic Retrograde CholangioPancreatography/Endoscopic Sphyncterotomy) during the same hospital admission
Exclusion Criteria
* Acute pancreatitis of etiology other than gallstones;
* Moderately-severe pancreatitis;
* Severe pancreatitis;
* Presence of pancreatic necrosis;
* Pregnant patients;
* Patients not able to sign the informed consent to take part in the study.
* Moderately-severe pancreatitis;
* Severe pancreatitis;
* Presence of pancreatic necrosis;
* Pregnant patients;
* Patients not able to sign the informed consent to take part in the study.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Università di Napoli Federico II
UNKNOWN
Sponsor Role
collaborator
Università della Campania Luigi Vanvitelli
UNKNOWN
Sponsor Role
collaborator
University of Cagliari
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mauro Podda
Prof.
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mauro Podda, MD
Role: STUDY_CHAIR
University of Cagliari, Department of Surgical Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Cagliari, Emergency Surgery Department
Cagliari, CA, Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ahmed Ali U, Issa Y, Hagenaars JC, Bakker OJ, van Goor H, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Brink MA, Schaapherder AF, Dejong CH, Spanier BW, Heisterkamp J, van der Harst E, van Eijck CH, Besselink MG, Gooszen HG, van Santvoort HC, Boermeester MA; Dutch Pancreatitis Study Group. Risk of Recurrent Pancreatitis and Progression to Chronic Pancreatitis After a First Episode of Acute Pancreatitis. Clin Gastroenterol Hepatol. 2016 May;14(5):738-46. doi: 10.1016/j.cgh.2015.12.040. Epub 2016 Jan 6.
Reference Type
BACKGROUND
Bagepally BS, Haridoss M, Sasidharan A, Jagadeesh KV, Oswal NK. Systematic review and meta-analysis of gallstone disease treatment outcomes in early cholecystectomy versus conservative management/delayed cholecystectomy. BMJ Open Gastroenterol. 2021 Jul;8(1):e000675. doi: 10.1136/bmjgast-2021-000675.
Reference Type
BACKGROUND
Chen Y, Chen TW, Wu CQ, Lin Q, Hu R, Xie CL, Zuo HD, Wu JL, Mu QW, Fu QS, Yang GQ, Zhang XM. Radiomics model of contrast-enhanced computed tomography for predicting the recurrence of acute pancreatitis. Eur Radiol. 2019 Aug;29(8):4408-4417. doi: 10.1007/s00330-018-5824-1. Epub 2018 Nov 9.
Reference Type
BACKGROUND
Cho JH, Jeong YH, Kim KH, Kim TN. Risk factors of recurrent pancreatitis after first acute pancreatitis attack: a retrospective cohort study. Scand J Gastroenterol. 2020 Jan;55(1):90-94. doi: 10.1080/00365521.2019.1699598. Epub 2019 Dec 10.
Reference Type
BACKGROUND
da Costa DW, Bouwense SA, Schepers NJ, Besselink MG, van Santvoort HC, van Brunschot S, Bakker OJ, Bollen TL, Dejong CH, van Goor H, Boermeester MA, Bruno MJ, van Eijck CH, Timmer R, Weusten BL, Consten EC, Brink MA, Spanier BWM, Bilgen EJS, Nieuwenhuijs VB, Hofker HS, Rosman C, Voorburg AM, Bosscha K, van Duijvendijk P, Gerritsen JJ, Heisterkamp J, de Hingh IH, Witteman BJ, Kruyt PM, Scheepers JJ, Molenaar IQ, Schaapherder AF, Manusama ER, van der Waaij LA, van Unen J, Dijkgraaf MG, van Ramshorst B, Gooszen HG, Boerma D; Dutch Pancreatitis Study Group. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. Lancet. 2015 Sep 26;386(10000):1261-1268. doi: 10.1016/S0140-6736(15)00274-3.
Reference Type
BACKGROUND
Ding N, Guo C, Li C, Zhou Y, Chai X. An Artificial Neural Networks Model for Early Predicting In-Hospital Mortality in Acute Pancreatitis in MIMIC-III. Biomed Res Int. 2021 Jan 28;2021:6638919. doi: 10.1155/2021/6638919. eCollection 2021.
Reference Type
BACKGROUND
Gurusamy KS, Nagendran M, Davidson BR. Early versus delayed laparoscopic cholecystectomy for acute gallstone pancreatitis. Cochrane Database Syst Rev. 2013 Sep 2;2013(9):CD010326. doi: 10.1002/14651858.CD010326.pub2.
Reference Type
BACKGROUND
Hong WD, Chen XR, Jin SQ, Huang QK, Zhu QH, Pan JY. Use of an artificial neural network to predict persistent organ failure in patients with acute pancreatitis. Clinics (Sao Paulo). 2013 Jan;68(1):27-31. doi: 10.6061/clinics/2013(01)rc01. No abstract available.
Reference Type
BACKGROUND
Mashayekhi R, Parekh VS, Faghih M, Singh VK, Jacobs MA, Zaheer A. Radiomic features of the pancreas on CT imaging accurately differentiate functional abdominal pain, recurrent acute pancreatitis, and chronic pancreatitis. Eur J Radiol. 2020 Feb;123:108778. doi: 10.1016/j.ejrad.2019.108778. Epub 2019 Dec 11.
Reference Type
BACKGROUND
Hu X, Yang B, Li J, Bai X, Li S, Liu H, Zhang H, Zeng F. Individualized Prediction of Acute Pancreatitis Recurrence Using a Nomogram. Pancreas. 2021 Jul 1;50(6):873-878. doi: 10.1097/MPA.0000000000001839.
Reference Type
BACKGROUND
Loozen CS, Oor JE, van Ramshorst B, van Santvoort HC, Boerma D. Conservative treatment of acute cholecystitis: a systematic review and pooled analysis. Surg Endosc. 2017 Feb;31(2):504-515. doi: 10.1007/s00464-016-5011-x. Epub 2016 Jun 17.
Reference Type
BACKGROUND
Mador BD, Panton ON, Hameed SM. Early versus delayed cholecystectomy following endoscopic sphincterotomy for mild biliary pancreatitis. Surg Endosc. 2014 Dec;28(12):3337-42. doi: 10.1007/s00464-014-3621-8. Epub 2014 Jun 25.
Reference Type
BACKGROUND
Nebiker CA, Frey DM, Hamel CT, Oertli D, Kettelhack C. Early versus delayed cholecystectomy in patients with biliary acute pancreatitis. Surgery. 2009 Mar;145(3):260-4. doi: 10.1016/j.surg.2008.10.012. Epub 2009 Feb 1.
Reference Type
BACKGROUND
Riquelme F, Marinkovic B, Salazar M, Martinez W, Catan F, Uribe-Echevarria S, Puelma F, Munoz J, Canals A, Astudillo C, Uribe M. Early laparoscopic cholecystectomy reduces hospital stay in mild gallstone pancreatitis. A randomized controlled trial. HPB (Oxford). 2020 Jan;22(1):26-33. doi: 10.1016/j.hpb.2019.05.013. Epub 2019 Jun 22.
Reference Type
BACKGROUND
Sankaran SJ, Xiao AY, Wu LM, Windsor JA, Forsmark CE, Petrov MS. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis. Gastroenterology. 2015 Nov;149(6):1490-1500.e1. doi: 10.1053/j.gastro.2015.07.066. Epub 2015 Aug 20.
Reference Type
BACKGROUND
Schmidt M, Sondenaa K, Vetrhus M, Berhane T, Eide GE. A randomized controlled study of uncomplicated gallstone disease with a 14-year follow-up showed that operation was the preferred treatment. Dig Surg. 2011;28(4):270-6. doi: 10.1159/000329464. Epub 2011 Jul 9.
Reference Type
BACKGROUND
Sharma A, Vans E, Shigemizu D, Boroevich KA, Tsunoda T. DeepInsight: A methodology to transform a non-image data to an image for convolution neural network architecture. Sci Rep. 2019 Aug 6;9(1):11399. doi: 10.1038/s41598-019-47765-6.
Reference Type
BACKGROUND
Stevens CL, Abbas SM, Watters DA. How Does Cholecystectomy Influence Recurrence of Idiopathic Acute Pancreatitis? J Gastrointest Surg. 2016 Dec;20(12):1997-2001. doi: 10.1007/s11605-016-3269-x. Epub 2016 Sep 23.
Reference Type
BACKGROUND
Umans DS, Hallensleben ND, Verdonk RC, Bouwense SAW, Fockens P, van Santvoort HC, Voermans RP, Besselink MG, Bruno MJ, van Hooft JE; Dutch Pancreatitis Study Group. Recurrence of idiopathic acute pancreatitis after cholecystectomy: systematic review and meta-analysis. Br J Surg. 2020 Feb;107(3):191-199. doi: 10.1002/bjs.11429. Epub 2019 Dec 25.
Reference Type
BACKGROUND
Werner J, Hartwig W, Uhl W, Muller C, Buchler MW. Useful markers for predicting severity and monitoring progression of acute pancreatitis. Pancreatology. 2003;3(2):115-27. doi: 10.1159/000070079.
Reference Type
BACKGROUND
Yamashita R, Nishio M, Do RKG, Togashi K. Convolutional neural networks: an overview and application in radiology. Insights Imaging. 2018 Aug;9(4):611-629. doi: 10.1007/s13244-018-0639-9. Epub 2018 Jun 22.
Reference Type
BACKGROUND
Yuan X, Xu B, Wong M, Chen Y, Tang Y, Deng L, Tang D. The safety, feasibility, and cost-effectiveness of early laparoscopic cholecystectomy for patients with mild acute biliary pancreatitis: A meta-analysis. Surgeon. 2021 Oct;19(5):287-296. doi: 10.1016/j.surge.2020.06.014. Epub 2020 Jul 22.
Reference Type
BACKGROUND
Zhou Y, Ge YT, Shi XL, Wu KY, Chen WW, Ding YB, Xiao WM, Wang D, Lu GT, Hu LH. Machine learning predictive models for acute pancreatitis: A systematic review. Int J Med Inform. 2022 Jan;157:104641. doi: 10.1016/j.ijmedinf.2021.104641. Epub 2021 Nov 10.
Reference Type
BACKGROUND
Podda M, Pisanu A, Pellino G, De Simone A, Selvaggi L, Murzi V, Locci E, Rottoli M, Calini G, Cardelli S, Catena F, Vallicelli C, Bova R, Vigutto G, D'Acapito F, Ercolani G, Solaini L, Biloslavo A, Germani P, Colutta C, Occhionorelli S, Lacavalla D, Sibilla MG, Olmi S, Uccelli M, Oldani A, Giordano A, Guagni T, Perini D, Pata F, Nardo B, Paglione D, Franco G, Donadon M, Di Martino M, Bruzzese D, Pacella D. Machine learning for the rElapse risk eValuation in acute biliary pancreatitis: The deep learning MINERVA study protocol. World J Emerg Surg. 2025 Mar 3;20(1):17. doi: 10.1186/s13017-025-00594-7.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MINERVA_1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
NCT01238341
COMPLETED
Post Pancreatitis Complications Study (Based on a Prospective Data Base)
NCT03284489
WITHDRAWN
Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
NCT06860984
RECRUITING
PHASE3
Effect of a Deep Learning-based Bile Duct Scanning System on the Diagnostic Accuracy of Common Bile Duct Stones During Examination by Novice Ultrasound Endoscopists
NCT05381064
UNKNOWN
NA
Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis
NCT02412826
UNKNOWN
Quality Assessment in Endoscopic Retrograde Cholangiopancreatography(ERCP)
NCT02698137
COMPLETED
The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders
NCT00861198
COMPLETED
Prediction of PEP Based on the Appearance of the Major Duodenal Papilla
NCT05800626
RECRUITING
Election of the Optimal Moment of Colecistectomy After Mild Biliary Pancreatitis
NCT04625712
COMPLETED
NA
Microbiological Assessment of Bile in Patients Undergone to Endoscopic Retrograde Cholangiography (ERCP): the "Microbile Registry"
NCT06115564
UNKNOWN
Trainee Involvement in ERCP Risk Score
NCT04341909
COMPLETED
Acute Biliary Pancreatitis - Optimal Time for Cholecystectomy
NCT03085407
COMPLETED
NA
Enhanced Recovery in Acute Pancreatitis
NCT02813876
COMPLETED
PHASE2
Prevalence and Predictive Factors of Difficult Biliary Cannulation
NCT06591364
NOT_YET_RECRUITING
ERCP-induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?
NCT02602574
UNKNOWN
Early Precut Versus Pancreatic Stent for Post-ERCP Pancreatitis
NCT02497872
COMPLETED
NA
Prognostic Score To Predict Major Complications After Pancreaticoduodenectomy
NCT01278381
COMPLETED
Diagnostic and Interventional Therapy in Acute Pancreatitis
NCT00699933
UNKNOWN
Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis
NCT07074379
RECRUITING
NA
Study on Predictive Factors, Safety and Efficacy of Endoscopic Retrograde Accessory Pancreatography in CP
NCT06684301
COMPLETED
A Register on the Quality of ERCP and Training of Endoscopists in Italy
NCT02971579
COMPLETED
Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
NCT04619511
COMPLETED
Prospective Evaluation of Idiopathic Pancreatitis: Role of Endoscopic Ultrasonography
NCT00609726
COMPLETED
Patient-reported Outcome Scale in Acute Pancreatitis
NCT03650062
COMPLETED
Evaluation of Difficulty Score for Robotic Pancreatoduodenectomy
NCT04662346
UNKNOWN
NA